[go: up one dir, main page]

DE69616303T2 - O-malonyltyrosyl-verbindungen, o-malonyltyrosyl-verbindungen enthaltende peptide und ihre verwendung - Google Patents

O-malonyltyrosyl-verbindungen, o-malonyltyrosyl-verbindungen enthaltende peptide und ihre verwendung Download PDF

Info

Publication number
DE69616303T2
DE69616303T2 DE69616303T DE69616303T DE69616303T2 DE 69616303 T2 DE69616303 T2 DE 69616303T2 DE 69616303 T DE69616303 T DE 69616303T DE 69616303 T DE69616303 T DE 69616303T DE 69616303 T2 DE69616303 T2 DE 69616303T2
Authority
DE
Germany
Prior art keywords
formula
group
peptide
domain
malonyltyrosyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69616303T
Other languages
German (de)
English (en)
Other versions
DE69616303D1 (de
Inventor
R. Terrence BURKE
Bin Ye
Miki Akamatsu
K. Hemanta KOLE
Xinjian Yan
R. Peter ROLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69616303D1 publication Critical patent/DE69616303D1/de
Application granted granted Critical
Publication of DE69616303T2 publication Critical patent/DE69616303T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69616303T 1995-03-31 1996-03-29 O-malonyltyrosyl-verbindungen, o-malonyltyrosyl-verbindungen enthaltende peptide und ihre verwendung Expired - Lifetime DE69616303T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/414,520 US5688992A (en) 1995-03-31 1995-03-31 O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US414520 1995-03-31
PCT/US1996/004311 WO1996030332A1 (fr) 1995-03-31 1996-03-29 Composes a base d'o-malonyltyrosyle, peptides contenant des composes a base d'o-malonyltyrosyle et leurs utilisations

Publications (2)

Publication Number Publication Date
DE69616303D1 DE69616303D1 (de) 2001-11-29
DE69616303T2 true DE69616303T2 (de) 2004-08-12

Family

ID=23641810

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69616303T Expired - Lifetime DE69616303T2 (de) 1995-03-31 1996-03-29 O-malonyltyrosyl-verbindungen, o-malonyltyrosyl-verbindungen enthaltende peptide und ihre verwendung

Country Status (8)

Country Link
US (1) US5688992A (fr)
EP (1) EP0820433B1 (fr)
JP (1) JP3929490B2 (fr)
AT (1) ATE207459T1 (fr)
AU (1) AU708929B2 (fr)
CA (1) CA2215827C (fr)
DE (1) DE69616303T2 (fr)
WO (1) WO1996030332A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5994522A (en) * 1997-01-24 1999-11-30 Washington University BLNK proteins
DE69824433D1 (en) * 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6410585B1 (en) * 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
US6156784A (en) * 1997-12-18 2000-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as phosphotyrosine mimics
WO2000027802A1 (fr) * 1998-11-12 2000-05-18 Ariad Pharmaceuticals, Inc. Inhibiteurs de transduction de signaux bicycliques, compositions les contenant et utilisation de ces dernieres
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
CA2368733C (fr) * 1999-03-23 2014-10-07 Terrence R. Burke, Jr. Derives de phenylalanine
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
ES2222753T3 (es) * 1999-04-15 2005-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Compuestos utiles como mimeticos de fosfotirosina.
WO2001028577A2 (fr) 1999-10-22 2001-04-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibition de la motilite cellulaire et de l'angiogenese
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
AU2001285133A1 (en) * 2000-08-22 2002-03-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services SH2 domain binding inhibitors
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
ES2872403T3 (es) 2013-03-14 2021-11-02 Childrens Medical Center Péptido Psap para el tratamiento de cánceres que expresan CD36
IT202000004849A1 (it) * 2020-03-06 2021-09-06 Univ Degli Studi Di Roma “Tor Vergata” Peptidi e loro usi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200546A (en) * 1991-09-30 1993-04-06 The United States Of America As Represented By The Department Of Health And Human Services Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
US5264607A (en) * 1991-09-30 1993-11-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Process of making benzylic α,α-diflurophosphonates from benzylic α-ketophosphorates
WO1994007913A1 (fr) * 1992-09-25 1994-04-14 Warner-Lambert Company Antagonistes peptidiques de la fixation du sh2 et leurs usages therapeutiques
WO1994008600A1 (fr) * 1992-10-09 1994-04-28 Joslin Diabetes Center Inhibition de molecules transductrices de signaux

Also Published As

Publication number Publication date
DE69616303D1 (de) 2001-11-29
ATE207459T1 (de) 2001-11-15
CA2215827A1 (fr) 1996-10-03
EP0820433A1 (fr) 1998-01-28
EP0820433B1 (fr) 2001-10-24
JP3929490B2 (ja) 2007-06-13
CA2215827C (fr) 2010-08-10
US5688992A (en) 1997-11-18
AU708929B2 (en) 1999-08-19
AU5377696A (en) 1996-10-16
JPH11505520A (ja) 1999-05-21
WO1996030332A1 (fr) 1996-10-03

Similar Documents

Publication Publication Date Title
DE69616303T2 (de) O-malonyltyrosyl-verbindungen, o-malonyltyrosyl-verbindungen enthaltende peptide und ihre verwendung
AU660465B2 (en) Increasing blood-brain barrier permeability with permeabilizer peptides
DE3789371T2 (de) Aryloxy- und Arylacyloxymethyl-Ketone als Thiolprotease-Hemmungsstoffe.
EP0034259B1 (fr) Peptides, procédé pour leur préparation et médicaments ou agents de diagnostic les contenant
DE69424298T2 (de) Durch glutathion-s-transferase aktivierte verbindungen
DE69528197T2 (de) Neue 1,3-dialkylharnstoff-derivate
DD243932A5 (de) Verfahren zur herstellung von n,n'-dialkylguanidino-dipeptiden
DE69633623T2 (de) Cystein-Protease-Inhibitoren für die Behandlung von allergischen Krankheiten verursacht duch IgE
EP1294742B1 (fr) Inhibiteurs de l'urokinase
DD217807A5 (de) Verfahren zur herstellung neuer substituierter tetrapeptide
DE69434070T2 (de) Kininogen-inhibitoren
EP1485345B1 (fr) Inhibiteurs de l'urokinase, leur production et leur utilisation
JP4603364B2 (ja) ペプチドギャップ結合モジュレーター
WO1992020362A1 (fr) Peptides favorisant le developpement de cellules nerveuses et leurs utilisations
DE60034959T2 (de) Hemmung der zellmotilität und angiogenese mit grb2 sh2-domäne inhibitoren
EP0137339B1 (fr) Peptides à activité pharmacologique
EP1551864B1 (fr) Substrats pour la détection de TAFI(a)
JPH08505143A (ja) ジフルオロペンタペプチド誘導体抗炎症剤
EP0056594B1 (fr) Fragments de thymosine alpha-1 et compositions pharmaceutiques à action immunorégulatrice qui les contiennent
US20250002532A1 (en) A novel peptide and the use thereof
CH636343A5 (de) Verfahren zur herstellung eines neuen tridecapeptids.
DE19815812A1 (de) Modifizierte Cytostatika
EP1794182B1 (fr) Composes modulant les actions de la trh et inhibant l'enzyme de degradation de trh
DE2900926C2 (fr)
EP0203450A2 (fr) Dérivés d'amino-acides bicycliques, leur procédé de préparation, les agents les contenant et leur emploi

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition